公开(公告)号：US06045797A

公开(公告)日：2000-04-04

申请号：US866381

申请日：1997-05-30

申请人： Ben Lewis Margolis ,  Joseph Schlessinger

发明人： Ben Lewis Margolis ,  Joseph Schlessinger

IPC分类号： A61P43/00 ,  C07K14/475 ,  C07K14/485 ,  C07K14/71 ,  A61K39/00 ,  C07K1/00

CPC分类号： C07K14/485 ,  C07K14/475 ,  C07K14/71

摘要： A method for treatment of a disease or condition in an organism characterized by an abnormal level of interaction between a BLM domain and its natural binding partner is described. The disease or condition may also be characterized by an abnormality in a signal transduction pathway, wherein the pathway contains a protein with a BLM domain. The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complex formed between the BLM domain-containing protein and its natural binding partner. A method for diagnosis of such a disease or condition by detecting the level of such interaction as an indication of that disease or condition is also described. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described. The invention also features a peptide comprising, consisting or consisting essentially of a BLM domain.

摘要翻译： 描述了用于治疗生物体中疾病或病症的方法，其特征在于BLM结构域与其天然结合配偶体之间的相互作用异常水平。 疾病或病症的特征还在于信号转导途径的异常，其中该途径含有具有BLM结构域的蛋白质。 该方法包括在体内破坏或促进相互作用（或信号）。 该方法还涉及抑制在含有BLM结构域的蛋白质与其天然结合配偶体之间形成的复合物的活性。 还描述了通过检测这种相互作用的水平来诊断这种疾病或病症的方法，作为该疾病或病症的指征。 此外，描述了通过测定潜在剂以破坏或促进该相互作用的能力来筛选可用于治疗这种疾病或病症的药剂的方法。 本发明还特征在于肽，其包含由BLM结构域组成或由其组成。